Muscular Adverse Events Associated with Statins
Abstract
Statins are an important group of lipid lowering medications that have helped to control cardiovascular mortality globally. Muscular side effects, mostly myalgia, is a known adverse event of statins. Intense physical activity, kidney or liver failure, hypothyroidism, inherited or metabolic myopathies, and some medications, are risk factors for statin-induced myalgia. Muscular adverse events are more often observed with higher doses or with the use of lipophilic statins. Much is not known about the precise mechanisms responsible for the statin related muscular adverse effects, a few hypothesis have been suggested. It is important to measure plasma creatine phosphokinase in subjects who encounter myalgia while being treated with statins. In this review we present some general safety information on muscular adverse events caused due to statins.
Downloads
References
LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282:2340–6.
Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455–61.
Mann DM, Woodward M, Muntner P, et al. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44: 1410–21.
Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med. 2016; 374:664–9.
Ward NC, Watts GF, Eckel RH. Statin toxicity. Circ Res. 2019;124:328–50.
Vonbank A, Drexel H, Agewall S, et al. Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review. Eur Heart J Cardiovasc Pharmacother. 2018;4:230–6.
Bruckert E, Hayem G, Dejager S et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403–14.
Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6:208–15. https://doi.org/10.1016/j.jacl.2012.03.003
Hovingh GK, Gandra SR, McKendrick J, et al. Identification and management of patients with statin-associated symptoms in clinical practice: a clinician survey. Atherosclerosis 2016; 245:111–7. https://doi.org/10.1016/j.atherosclerosis.2015.12.015
Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, et al; GAUSS-3 investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA 2016; 315:1580–90.
Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, et al; Scripps Mercy Clinical Research Center. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002;137: 581–5.
SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L et al. SLCO1B1 variants and statin-induced myopathy--a genome wide study. N Engl J Med. 2008;359(8):789-99.
Saxon DR, Eckel RH. Statin intolerance: a literature review and management strategies. Prog Cardiovasc Dis 2016; 59:153–64. https://doi.org/10.1016/j.pcad.2016.07.009
Laaksonen R, Jokelainen K, Laakso J, et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol. 1996; 77:851–4.
Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme Q10 on myopathic symp-toms in patients treated with statins. Am J Cardiol. 2007; 99:1409–12.
Sirvent P, Mercier J, Lacampagne A. New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol. 2008;8:333–8. https://doi.org/10.1016/j.coph.2007.12.010
Copyright (c) 2021 Reena Royal et al.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
